| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.4 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.4 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.4 |
| mRNA | NVP-ADW742 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.035 | 0.4 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.5 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |